Amgen AMGN

NAS: AMGN | ISIN: US0311621009   10/04/2026
351,02 USD (-1,29%)
(-1,29%)   10/04/2026

6 april 2026 · Amgen Announces Positive Topline Phase 3 Results For Subcutaneous Tepezza® In Adults Living With Moderate-To-Severe Active Thyroid Eye Disease · Persbericht

28 maart 2026 · Repatha® Cuts Risk Of First Major Cardiovascular Events By 31% In High-Risk Patients Without Known Significant Atherosclerosis · Persbericht

5 maart 2026 · Amgen To Present At The Leerink Partners 2026 Global Healthcare Conference · Persbericht

4 maart 2026 · Amgen Announces 2026 Second Quarter Dividend · Persbericht

24 februari 2026 · Amgen To Present At The 46Th Annual Td Cowen Health Care Conference · Persbericht

13 februari 2026 · Amgen To Present At Citi's 2026 Virtual Oncology Leadership Summit · Persbericht

12 februari 2026 · La Commission Europeenne Approuve Uplizna® D'amgen Dans Le Cadre Du Traitement De La Myasthénie Grave Généralisée · Persbericht

3 februari 2026 · Amgen Reports Fourth Quarter And Full Year 2025 Financial Results · Persbericht

28 januari 2026 · Amgen Announces Webcast Of 2025 Fourth Quarter And Full Year Financial Results · Persbericht

7 januari 2026 · Amgen To Present At The 44Th Annual J.p. Morgan Healthcare Conference · Persbericht

6 januari 2026 · Amgen Acquires Dark Blue Therapeutics, Bolstering Oncology Pipeline · Persbericht

19 december 2025 · Amgen Takes Action With The U.s. Government To Lower The Cost Of Medicines For American Patients · Persbericht

12 december 2025 · Fda Approves Uplizna® For Adults With Generalized Myasthenia Gravis · Persbericht

9 december 2025 · Amgen Announces 2026 First Quarter Dividend · Persbericht

24 november 2025 · Amgen To Present At Citi's 2025 Global Healthcare Conference · Persbericht

24 november 2025 · Amgen To Present At The 8Th Annual Evercore Isi Healthconx Conference · Persbericht

19 november 2025 · Fda Grants Full Approval To Amgen's Imdelltra® In Extensive Stage Small Cell Lung Cancer · Persbericht

8 november 2025 · Amgen's Repatha® Cuts Risk Of First Major Adverse Cardiovascular Events By 25% In Landmark Phase 3 Vesalius-Cv Trial · Persbericht

4 november 2025 · Amgen Reports Third Quarter 2025 Financial Results · Persbericht

31 oktober 2025 · Amgen Announces 2025 Fourth Quarter Dividend · Persbericht

Mijn selecties